High cost of dalteparin not worth added benefits in cancer

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.476, 2005-01, pp. : 4-4

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Evidence for the Benefits of the Low-Molecular-Weight Heparin Dalteparin in ‘High-Risk’ Patients with Acute Coronary Syndromes

Heart Drug, Vol. 4, Iss. 3, 2004-08 ,pp. : 157-163

Karger

Access to resources Recommend Favorite

Cancer cost high in Germany

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 551, 2008-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Dual antiplatelet therapy: no added benefits for high-risk patients

Inpharma, Vol. 1, Iss. 1529, 2006-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Multidisciplinary high-intensity hepatitis C clinic worth its extra cost

Inpharma, Vol. 1, Iss. 1341, 2002-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Dalteparin cost-effective for postop DVT prophylaxis

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 573, 2009-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite